Faster treatments for future pandemics (Brisbane) Investigating the DNA factory in our bodies that makes everything (Melbourne) MELBOURNE and BRISBANE; October 27, 2021: Two Australian scientists...

MELBOURNE, AU and KING OF PRUSSIA, PA; October 19/18, 2021: Two of Melbourne’s most prominent medical research and drug development organisations, WEHI and CSL, have joined forces to create a...

CSL Reaffirms Commitment to Manufacture AstraZeneca COVID Vaccine into 2022 Melbourne, Australia: CSL is committed to the manufacture of approximately 50 million doses of the AstraZeneca COVID-19...

CSL Requires COVID-19 Vaccination for On-Site Employees and Visitors Melbourne, Australia: CSL has confirmed all Australian on-site employees, contractors and visitors will be required to be...

CSL confirms there was a positive COVID-19 case at its Broadmeadows manufacturing facility last week. All employees and contractors who were present at the same time as the confirmed case have...

$2.5 Million Funding Available to Australian Biomedical Researchers Melbourne, Australia: 01.06.2021: Australia’s top biomedical researchers are invited to apply for one of two CSL Centenary...

New Patent Box policy will benefit domestic commercialisation of medical research Melbourne, Australia: CSL welcomes the Federal Government’s Budget commitment to introduce a Patent Box that...

Onshore mRNA manufacturing will build Australian capability for next generation vaccine technologies Melbourne, Australia: CSL welcomes the Government’s plan to further develop onshore mRNA...

Etranacogene dezaparvovec (AMT-061) is an investigational gene therapy that may potentially provide people with hemophilia B with years of functional levels of Factor IX, a blood-clotting protein...

Melbourne, Australia: CSL can confirm that production of the AstraZeneca COVID-19 vaccine for Australia has reached more than a million doses a week - these volumes have been produced for a number...

Four Australian Research Programs to be Fast-Tracked in Partnership with CSL Melbourne, Australia: Four Australian medical researcher programs have been awarded a CSL Research Acceleration...

CSL remains committed to meeting its contracted arrangements with the Australian Government and AstraZeneca for locally produced AstraZeneca COVID-19 vaccines. We will continue our focused and...

CSL continues to provide medicines to patients around the world. Safeguarding our people, patients and donors remains our top priority. As the COVID-19 pandemic evolves, CSL continues to provide...

Here is how CSL is working around the world with academia, industry and governments to combat the novel coronavirus COVID-19 CSL and AstraZeneca have agreed for CSL to manufacture approximately 50...

Melbourne, 24 March 2021 – CSL Limited (ASX:CSL) has released 830,000 locally made doses of the AstraZeneca COVID-19 vaccine, ahead of initial scheduling. The release follows the completion of...

CSL is pleased to confirm that the final stages of manufacturing of the AstraZeneca COVID-19 vaccine for Australia are planned to commence next week, with first doses on track for release towards...

24 healthy volunteers to be recruited for study of plasma-derived COVID-19 Immunoglobulin January 31, 2021, Melbourne: CSL Behring Australia, a subsidiary of CSL Limited, today announced that...

CSL Commences Manufacturing of University of Oxford/AstraZeneca Vaccine Candidate in Melbourne. November 8, 2020, Melbourne — CSL Limited (ASX:CSL) CSL today confirmed it will commence...

Two Australian scientists have each been awarded CSL Centenary Fellowships, valued at $1.25 million over five years, to investigate new ways to fight two of the world’s biggest health...

October 8, 2020, Melbourne — CSL Limited (ASX:CSL; USOTC:CSLLY) today announces that its subsidiary, Seqirus, has signed a final agreement (Agreement) with the Commonwealth of Australia for the...

CSL has appointed Ms Joy Linton, a well-respected global leader with extensive strategic and financial experience as Chief Financial Officer (CFO.) Ms Linton will be based at CSL’s Head Office...

CSL Limited (ASX:CSL) today announced it has signed a Heads of Agreement (HoA) with the Australian Government for the supply of 51 million doses of the University of Queensland’s (UQ) COVID-19...

Development of the University of Queensland’s vaccine candidate remains CSL’s priority. However, we are currently in discussions with AstraZeneca and the Australian Government to assess...

Washington, D.C., July 30, 2020 – At today’s White House Roundtable, plasma industry leader and CSL CEO Paul Perreault urged people who have recovered from COVID-19 to consider donating plasma...

The report made by the Courier Mail and other media agencies today that an agreement has been struck to specifically secure supply, when a vaccine is available, for Queensland, is incorrect. In...

Economist Intelligence Unit (EIU) Report launched today reveals only one in three rare disease patients receives the best-available, evidence-based care. Less than a third of surveyed healthcare...

Today, the first human trials using the University of Queensland’s (UQ) COVID-19 vaccine have commenced in Australia The first human trials using the University of Queensland’s (UQ) COVID-19...

Applications are now open for the 2021 CSL Centenary Fellowships, which are offered to outstanding mid-career scientists seeking to undertake world-class medical research at an Australian academic...

Plasma-derived therapeutic with potential to treat serious complications of COVID-19. MELBOURNE, AUSTRALIA – CSL Behring Australia, a subsidiary of CSL Limited, today announced that it will...

To speed treatments, global biotech leader CSL offers to lend the company’s expertise in science and manufacturing. Anthony Farina – Chief Communications Officer, CSL Limited 18 Mar 2020 As...

CSL Limited's statement on Coronavirus Coronavirus is quite different to influenza virus so it is not a core area of focus for CSL or Seqirus. However, we have investigated possible adjacencies in...

Forbes Magazine named CSL among its Best Employers for Diversity 2020. The annual rankings, which measure diversity across six different categories, are based on an independent survey of more than...

The Honourable John Brumby AO today formally opened the new ‘Nancy Millis’ building, an expansion of the Bio21 Institute of Molecular Science and Biotechnology, University of Melbourne,...

CSL statement in response to media reports on case against Joseph Chiao The Sydney Morning Herald on 18 October 2019 reported that former CSL employee Dr Joseph Chiao ‘stole patient data’. CSL...

Global biotechnology leader, CSL, celebrated the Company’s 25th Anniversary of listing on the Australian Securities Exchange (ASX), commemorating the occasion with a ceremonial bell ring at...

Two Australian scientists have each been awarded AUD$1.25 million CSL Centenary Fellowships over five years to improve treatments for two of the world’s biggest health challenges: malaria and...

Major landmark development will significantly increase CSL’s presence in the Parkville biomedical precinct and cement Melbourne’s place as a world-class research destination MELBOURNE,...

MELBOURNE, Australia - CSL today announced its continued partnership with the National Youth Science Forum (NYSF) signing a new three-year agreement in support of programs that encourage life-long...

The Honourable John Brumby AO today formally opened the new ‘Nancy Millis’ building, an expansion of the Bio21 Institute of Molecular Science and Biotechnology, University of Melbourne,...

CSL spotlights developments in cell-based vaccine technology at Australian Research and Development briefing CSL Limited (ASX:CSL; USOTC:CSLLY) subsidiary Seqirus, today presented new real-world...

Two Australian scientists have each been awarded an AUD$1.25 million, five-year, CSL Centenary Fellowship to further research into why so many people die from infection following stroke and how we...

$2.5 Million Funding Available to Australian Biomedical Researchers Melbourne, Australia: 01.06.2018 - Australia’s best and brightest biomedical researchers are invited to apply for one of two...

CSL Limited today announced a revised profit outlook for fiscal 2018. CSL Limited (ASX:CSL; USOTC:CSLLY) today announced a revised profit outlook for fiscal 2018. The Company now expects net...

Dr Brian McNamee AO and Mr Abbas Hussain have been appointed as independent Non-Executive Directors, effective 14 February 2018. CSL (ASX:CSL; USOTC:CSLLY) today announced that Dr Brian McNamee AO...

CSL Behring today announced that it has signed an agreement with the National Blood Authority, representing all Australian governments, to continue to provide the community with a world-class and...

CSL today officially opened a new AUD$230 million advanced manufacturing facility at its CSL Behring site in Broadmeadows with the assistance of Victorian Minister for Industry and Employment, Ben...

The study will be the largest ever undertaken by CSL, and will enroll more than 17,000 patients from approximately 1,000 sites around the world. Jemimah Pentland 05 Dec 2017 Global biotherapeutics...

Two Australian scientists have each been awarded an AUD$1.25 million, five-year, CSL Centenary Fellowship to further research into gentler, more effective cancer diagnostics and, to advance...

Australia’s biomedical researchers are invited to apply for one of two CSL Centenary Fellowships each worth $1.25million over five years in support of discovery and translational medical...

An international team of scientists in collaboration with global biotechnology leader CSL has successfully prevented the progression of Diabetic Kidney Disease (DKD) in laboratory studies of type...